Sign In
Buy SUPN
$44.04
-0.0350 (-0.0794%)
At Close: Jun 03, 2026
Supernus Announces First Quarter 2024 Financial Results
04:05pm, Wednesday, 08'th May 2024
ROCKVILLE, Md., May 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:20am, Tuesday, 07'th May 2024
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Supernus (SUPN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the q
MEXICO CITY , May 7, 2024 /PRNewswire/ -- M8 Pharmaceuticals, an Acino company ('M8') announces that the company has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc. (Nasda
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
08:00pm, Monday, 06'th May 2024
NEW YORK , May 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN). Such investors are
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
08:17pm, Wednesday, 01'st May 2024
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) investors con
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
08:00am, Wednesday, 01'st May 2024
ROCKVILLE, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Actress, author, podcaster, and mother of two, Busy Philipps is teaming up with Supernus Pharmaceuticals to share her personal journey with attention-d
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
07:20pm, Monday, 29'th Apr 2024
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) (NASDAQ: SUPN) on behalf of investors
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
10:15am, Sunday, 28'th Apr 2024
NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN). Such investor
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
04:05pm, Wednesday, 24'th Apr 2024
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
11:00am, Saturday, 20'th Apr 2024
NEW YORK , April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN). Such investors
Supernus Provides Regulatory Update for SPN-830
08:00am, Monday, 08'th Apr 2024
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Supernus to Participate in Two Upcoming Investor Conferences
04:30pm, Wednesday, 06'th Mar 2024
ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
04:30pm, Wednesday, 28'th Feb 2024
ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript
09:41pm, Tuesday, 27'th Feb 2024
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
08:31pm, Tuesday, 27'th Feb 2024
Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Str
